NCT06830382View on ClinicalTrials.gov

HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2030

Study Completion Date

April 1, 2032

Conditions
Breast Cancer Stage IVHER2-low Breast CancerMolecular Imaging
Interventions
DIAGNOSTIC_TEST

Positron emission tomografy with [68Ga]Ga-ABY-025

Investigational Medicinal product (IMP):\[68Ga\]Ga-ABY-025 (all patients)

Sponsors

Collaborators (1)

Affibody
All Listed Sponsors
collaborator

Karolinska Institutet

OTHER

collaborator

Affibody

INDUSTRY

lead

Renske Altena

OTHER